BR9709443B1 - n-7-heterociclil-pirrol[2,3-d]pirimidinas, bem como composições farmacêuticas compreendendo as mesmas. - Google Patents

n-7-heterociclil-pirrol[2,3-d]pirimidinas, bem como composições farmacêuticas compreendendo as mesmas.

Info

Publication number: BR9709443B1
Authority: BR; Brazil
Prior art keywords: pct; pyrimidines; pyrrol; heterocyclyl; well
Prior art date: 1996-03-15

Application number

BRPI9709443-9A

Other languages

English (en)

Other versions

BR9709443A (pt

Inventor

Eva Altmann

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-03-15

Filing date

1997-03-05

Publication date

2009-05-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4192986&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9709443(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-03-05 Application filed filed Critical

1999-08-10 Publication of BR9709443A publication Critical patent/BR9709443A/pt

2009-05-05 Publication of BR9709443B1 publication Critical patent/BR9709443B1/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

BRPI9709443-9A 1996-03-15 1997-03-05 n-7-heterociclil-pirrol[2,3-d]pirimidinas, bem como composições farmacêuticas compreendendo as mesmas. BR9709443B1 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CH69496		1996-03-15
PCT/EP1997/001095 WO1997034895A1 (de)	1996-03-15	1997-03-05	NEUE N-7 HETEROCYCLYL-PYRROLO[2,3-d]PYRIMIDINE UND IHRE VERWENDUNG

Publications (2)

Publication Number	Publication Date
BR9709443A BR9709443A (pt)	1999-08-10
BR9709443B1 true BR9709443B1 (pt)	2009-05-05

Family

ID=4192986

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI9709443-9A BR9709443B1 (pt)	1996-03-15	1997-03-05	n-7-heterociclil-pirrol[2,3-d]pirimidinas, bem como composições farmacêuticas compreendendo as mesmas.

Country Status (16)

Country	Link
US (1)	US6051577A (pt)
EP (1)	EP0888353B1 (pt)
JP (1)	JP4326024B2 (pt)
KR (1)	KR20000064601A (pt)
CN (1)	CN1079796C (pt)
AT (1)	ATE244719T1 (pt)
AU (1)	AU716383B2 (pt)
BR (1)	BR9709443B1 (pt)
CA (1)	CA2249739A1 (pt)
DE (1)	DE59710417D1 (pt)
DK (1)	DK0888353T3 (pt)
ES (1)	ES2203793T3 (pt)
NO (1)	NO313239B1 (pt)
NZ (1)	NZ331804A (pt)
PT (1)	PT888353E (pt)
WO (1)	WO1997034895A1 (pt)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6251911B1 (en)	1996-10-02	2001-06-26	Novartis Ag	Pyrimidine derivatives and processes for the preparation thereof
GB9704948D0 (en)	1997-03-11	1997-04-30	Knoll Ag	Therapeutic agents
IL131582A0 (en) *	1997-03-19	2001-01-28	Basf Ag	Pyrrolo [2,3d] pyrimidines and their use as tyrosine kinase inhibitors
US7863444B2 (en)	1997-03-19	2011-01-04	Abbott Laboratories	4-aminopyrrolopyrimidines as kinase inhibitors
TWI242011B (en)	1997-03-31	2005-10-21	Eisai Co Ltd	1,4-substituted cyclic amine derivatives
AU753555C (en) *	1998-09-18	2003-07-03	Abbott Gmbh & Co. Kg	Pyrrolopyrimidines as protein kinase inhibitors
US6713474B2 (en) *	1998-09-18	2004-03-30	Abbott Gmbh & Co. Kg	Pyrrolopyrimidines as therapeutic agents
UA71587C2 (uk) *	1998-11-10	2004-12-15	Шерінг Акцієнгезелльшафт	Аміди антранілової кислоти та їхнє застосування як лікарських засобів
US7071199B1 (en)	1999-09-17	2006-07-04	Abbott Gmbh & Cco. Kg	Kinase inhibitors as therapeutic agents
WO2001072751A1 (en) *	2000-03-29	2001-10-04	Knoll Gesellschaft Mit Beschraenkter Haftung	Pyrrolopyrimidines as tyrosine kinase inhibitors
GB0226370D0 (en) *	2002-11-12	2002-12-18	Novartis Ag	Organic compounds
UA80171C2 (en) *	2002-12-19	2007-08-27	Pfizer Prod Inc	Pyrrolopyrimidine derivatives
AR043692A1 (es) *	2003-02-06	2005-08-10	Novartis Ag	2-cianopirrolopirimidinas y sus usos farmaceuticos
EP1719771A1 (en) *	2004-02-19	2006-11-08	Takeda Pharmaceutical Company Limited	Pyrazoloquinolone derivative and use thereof
JP4842929B2 (ja) *	2004-05-27	2011-12-21	ファイザー・プロダクツ・インク	癌治療に有用なピロロピリミジン誘導体
TW201307354A (zh) *	2005-12-29	2013-02-16	Abbott Lab	蛋白質激酶抑制劑
JP2009528991A (ja) *	2006-02-14	2009-08-13	バーテックスファーマシューティカルズインコーポレイテッド	プロテインキナーゼの阻害剤として有用なピロロ（３，２−ｃ）ピリジン
MX2011004824A (es)	2008-11-07	2012-01-12	Triact Therapeutics Inc	Uso de derivados de butano catecólico en terapia contra el cáncer.
US8426428B2 (en)	2008-12-05	2013-04-23	Principia Biopharma, Inc.	EGFR kinase knockdown via electrophilically enhanced inhibitors
EP2400985A2 (en)	2009-02-25	2012-01-04	OSI Pharmaceuticals, LLC	Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
EP2400990A2 (en)	2009-02-26	2012-01-04	OSI Pharmaceuticals, LLC	In situ methods for monitoring the emt status of tumor cells in vivo
WO2010099138A2 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099363A1 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8465912B2 (en)	2009-02-27	2013-06-18	OSI Pharmaceuticals, LLC	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010107968A1 (en)	2009-03-18	2010-09-23	Osi Pharmaceuticals, Inc.	Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
WO2011058164A1 (en)	2009-11-13	2011-05-19	Pangaea Biotech, S.A.	Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
EP2468883A1 (en)	2010-12-22	2012-06-27	Pangaea Biotech S.L.	Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
US9134297B2 (en)	2011-01-11	2015-09-15	Icahn School Of Medicine At Mount Sinai	Method and compositions for treating cancer and related methods
EP2492688A1 (en)	2011-02-23	2012-08-29	Pangaea Biotech, S.A.	Molecular biomarkers for predicting response to antitumor treatment in lung cancer
WO2012129145A1 (en)	2011-03-18	2012-09-27	OSI Pharmaceuticals, LLC	Nscle combination therapy
WO2012149014A1 (en)	2011-04-25	2012-11-01	OSI Pharmaceuticals, LLC	Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
RU2614254C2 (ru)	2011-08-31	2017-03-24	Дженентек, Инк.	Диагностические маркеры
MX2014003698A (es)	2011-09-30	2014-07-28	Genentech Inc	Marcadores de diagnostico.
WO2013152252A1 (en)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
WO2013190089A1 (en)	2012-06-21	2013-12-27	Pangaea Biotech, S.L.	Molecular biomarkers for predicting outcome in lung cancer
BR112014032913A2 (pt) *	2012-06-29	2017-06-27	Pfizer	novas 4-(amino-substituídas)-7h-pirrolo[2,3-d]pirimidinas como inibidores de lrrk2
WO2014134202A1 (en)	2013-02-26	2014-09-04	Triact Therapeutics, Inc.	Cancer therapy
WO2014145576A2 (en)	2013-03-15	2014-09-18	Northwestern University	Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer
US20160051556A1 (en)	2013-03-21	2016-02-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method and Pharmaceutical Composition for use in the Treatment of Chronic Liver Diseases Associated with a Low Hepcidin Expression
CA2923667A1 (en)	2013-09-09	2015-03-12	Triact Therapeutics, Inc.	Cancer therapy
EP3083618B1 (en)	2013-12-17	2018-02-21	Pfizer Inc	Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
US20170027940A1 (en)	2014-04-10	2017-02-02	Stichting Het Nederlands Kanker Instituut	Method for treating cancer
CN107223163A (zh)	2014-12-24	2017-09-29	豪夫迈·罗氏有限公司	用于膀胱癌症的治疗，诊断和预后方法
EP3350178B1 (en)	2015-09-14	2021-10-20	Pfizer Inc.	Novel imidazo [4,5-c]quinoline and imidazo [4,5-c][1,5]naphthyridine derivatives as lrrk2 inhibitors
PT3411358T (pt)	2016-02-04	2022-01-19	Takeda Pharmaceuticals Co	Composto de piperidina substituído e a sua utilização
CN107513068A (zh) *	2016-06-16	2017-12-26	中国科学院上海药物研究所	一种具有fgfr抑制活性的新型化合物及其制备和应用
KR20230150408A (ko)	2016-12-22	2023-10-30	암젠 인크	폐암, 췌장암 또는 대장암을 치료하기 위한 kras g12c 억제제로서의 벤즈이소티아졸, 이소티아졸로[3,4-b]피리딘, 퀴나졸린, 프탈라진, 피리도[2,3-d]피리다진 및 피리도[2,3-d]피리미딘 유도체
AR110963A1 (es)	2017-02-07	2019-05-22	Dae Woong Pharma	Compuestos heterocíclicos, su método de preparación y composición farmacéutica que los comprende
JOP20190272A1 (ar)	2017-05-22	2019-11-21	Amgen Inc	مثبطات kras g12c وطرق لاستخدامها
AU2018329920B2 (en)	2017-09-08	2022-12-01	Amgen Inc.	Inhibitors of KRAS G12C and methods of using the same
MA52501A (fr)	2018-05-04	2021-03-10	Amgen Inc	Inhibiteurs de kras g12c et leurs procédés d'utilisation
AU2019262599B2 (en)	2018-05-04	2023-10-12	Amgen Inc.	KRAS G12C inhibitors and methods of using the same
MA52564A (fr)	2018-05-10	2021-03-17	Amgen Inc	Inhibiteurs de kras g12c pour le traitement du cancer
EP3802535B1 (en)	2018-06-01	2022-12-14	Amgen, Inc	Kras g12c inhibitors and methods of using the same
AU2019284472B2 (en)	2018-06-11	2024-05-30	Amgen Inc.	KRAS G12C inhibitors for treating cancer
US11285156B2 (en)	2018-06-12	2022-03-29	Amgen Inc.	Substituted piperazines as KRAS G12C inhibitors
JP2022512584A (ja)	2018-10-04	2022-02-07	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	角皮症を処置するためのｅｇｆｒインヒビター
JP7516029B2 (ja)	2018-11-16	2024-07-16	アムジエン・インコーポレーテツド	Ｋｒａｓｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7377679B2 (ja)	2018-11-19	2023-11-10	アムジエン・インコーポレーテツド	がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
MX2021005700A (es)	2018-11-19	2021-07-07	Amgen Inc	Inhibidores de kras g12c y metodos de uso de los mismos.
EP3898592B1 (en)	2018-12-20	2024-10-09	Amgen Inc.	Heteroaryl amides useful as kif18a inhibitors
KR102875569B1 (ko)	2018-12-20	2025-10-23	암젠 인크	Kif18a 억제제
CA3123042A1 (en)	2018-12-20	2020-06-25	Amgen Inc.	Kif18a inhibitors
MX419368B (es)	2018-12-20	2025-01-14	Amgen Inc	Heteroarilamidas utiles como inhibidores de kif18a
CN113727758A (zh)	2019-03-01	2021-11-30	锐新医药公司	双环杂环基化合物及其用途
AU2020232242A1 (en)	2019-03-01	2021-09-09	Revolution Medicines, Inc.	Bicyclic heteroaryl compounds and uses thereof
EP3738593A1 (en)	2019-05-14	2020-11-18	Amgen, Inc	Dosing of kras inhibitor for treatment of cancers
CA3140392A1 (en)	2019-05-21	2020-11-26	Amgen Inc.	Solid state forms
AU2020324406A1 (en)	2019-08-02	2022-03-17	Amgen Inc.	KIF18A inhibitors
ES3051917T3 (en)	2019-08-02	2025-12-30	Amgen Inc	Kif18a inhibitors
CA3147276A1 (en)	2019-08-02	2021-02-11	Amgen Inc.	Kif18a inhibitors
US20220281843A1 (en)	2019-08-02	2022-09-08	Amgen Inc.	Kif18a inhibitors
AU2020369569A1 (en)	2019-10-24	2022-04-14	Amgen Inc.	Pyridopyrimidine derivatives useful as KRAS G12C and KRAS G12D inhibitors in the treatment of cancer
CN120699039A (zh)	2019-11-04	2025-09-26	锐新医药公司	Ras抑制剂
BR112022008535A2 (pt)	2019-11-04	2022-08-09	Revolution Medicines Inc	Composto, composição farmacêutica, métodos para tratar câncer e um distúrbio relativo à proteína ras
WO2021091982A1 (en)	2019-11-04	2021-05-14	Revolution Medicines, Inc.	Ras inhibitors
US20210139517A1 (en)	2019-11-08	2021-05-13	Revolution Medicines, Inc.	Bicyclic heteroaryl compounds and uses thereof
TW202532412A (zh)	2019-11-14	2025-08-16	美商安進公司	Kras g12c抑制劑化合物之改善的合成
AU2020383535A1 (en)	2019-11-14	2022-05-05	Amgen Inc.	Improved synthesis of KRAS G12C inhibitor compound
JP2023505100A (ja)	2019-11-27	2023-02-08	レボリューションメディシンズインコーポレイテッド	共有ｒａｓ阻害剤及びその使用
JP2023509701A (ja)	2020-01-07	2023-03-09	レヴォリューション・メディスンズ，インコーポレイテッド	Ｓｈｐ２阻害剤投薬およびがんを処置する方法
KR20230042600A (ko)	2020-06-18	2023-03-28	레볼루션 메디슨즈, 인크.	Ras 억제제에 대한 획득된 저항성을 지연, 예방, 및 치료하는 방법
CA3187757A1 (en)	2020-09-03	2022-03-24	Ethan AHLER	Use of sos1 inhibitors to treat malignancies with shp2 mutations
MX2023003060A (es)	2020-09-15	2023-04-05	Revolution Medicines Inc	Derivados indolicos como inhibidores de ras en el tratamiento del cancer.
JP2024501280A (ja)	2020-12-22	2024-01-11	キル・レガー・セラピューティクス・インコーポレーテッド	Ｓｏｓ１阻害剤およびその使用
CR20230558A (es)	2021-05-05	2024-01-24	Revolution Medicines Inc	Inhibidores de ras para el tratamiento del cáncer
CN117500811A (zh)	2021-05-05	2024-02-02	锐新医药公司	共价ras抑制剂及其用途
CN118561952A (zh)	2021-05-05	2024-08-30	锐新医药公司	Ras抑制剂
AR127308A1 (es)	2021-10-08	2024-01-10	Revolution Medicines Inc	Inhibidores ras
EP4448526A1 (en)	2021-12-17	2024-10-23	Genzyme Corporation	Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en)	2022-02-11	2023-08-16	Genzyme Corporation	Pyrazolopyrazine compounds as shp2 inhibitors
CN118829629A (zh)	2022-03-07	2024-10-22	美国安进公司	用于制备4-甲基-2-丙-2-基-吡啶-3-甲腈的方法
JP2025510572A (ja)	2022-03-08	2025-04-15	レボリューションメディシンズインコーポレイテッド	免疫不応性肺癌を治療するための方法
CN119998298A (zh)	2022-06-10	2025-05-13	锐新医药公司	大环ras抑制剂
EP4601644A1 (en)	2022-10-14	2025-08-20	Black Diamond Therapeutics, Inc.	Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
AU2024241633A1 (en)	2023-03-30	2025-11-06	Revolution Medicines, Inc.	Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024211712A1 (en)	2023-04-07	2024-10-10	Revolution Medicines, Inc.	Condensed macrocyclic compounds as ras inhibitors
AR132338A1 (es)	2023-04-07	2025-06-18	Revolution Medicines Inc	Inhibidores de ras
TW202448897A (zh)	2023-04-14	2024-12-16	美商銳新醫藥公司	Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法
CN121100123A (zh)	2023-04-14	2025-12-09	锐新医药公司	Ras抑制剂的结晶形式
WO2024229406A1 (en)	2023-05-04	2024-11-07	Revolution Medicines, Inc.	Combination therapy for a ras related disease or disorder
WO2025034702A1 (en)	2023-08-07	2025-02-13	Revolution Medicines, Inc.	Rmc-6291 for use in the treatment of ras protein-related disease or disorder
TW202530228A (zh)	2023-10-12	2025-08-01	美商銳新醫藥公司	Ｒａｓ抑制劑
WO2025137507A1 (en)	2023-12-22	2025-06-26	Regor Pharmaceuticals, Inc.	Sos1 inhibitors and uses thereof
WO2025171296A1 (en)	2024-02-09	2025-08-14	Revolution Medicines, Inc.	Ras inhibitors
US20250375445A1 (en)	2024-06-07	2025-12-11	Revolution Medicines, Inc.	Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en)	2024-06-21	2025-12-26	Revolution Medicines, Inc.	Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en)	2024-06-28	2026-01-02	Revolution Medicines, Inc.	Ras inhibitors
WO2026015790A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026015825A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026015801A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI933303A7 (fi) *	1991-01-23	1993-08-31	Gensia Inc	Adenosiinikinaasi-inhibiittoreita

1997
- 1997-03-05 NZ NZ331804A patent/NZ331804A/xx unknown
- 1997-03-05 CA CA002249739A patent/CA2249739A1/en not_active Abandoned
- 1997-03-05 JP JP53308197A patent/JP4326024B2/ja not_active Expired - Fee Related
- 1997-03-05 AU AU21534/97A patent/AU716383B2/en not_active Ceased
- 1997-03-05 EP EP97914189A patent/EP0888353B1/de not_active Expired - Lifetime
- 1997-03-05 US US09/142,548 patent/US6051577A/en not_active Expired - Fee Related
- 1997-03-05 AT AT97914189T patent/ATE244719T1/de active
- 1997-03-05 PT PT97914189T patent/PT888353E/pt unknown
- 1997-03-05 WO PCT/EP1997/001095 patent/WO1997034895A1/de not_active Ceased
- 1997-03-05 DE DE59710417T patent/DE59710417D1/de not_active Expired - Lifetime
- 1997-03-05 KR KR1019980707280A patent/KR20000064601A/ko not_active Ceased
- 1997-03-05 ES ES97914189T patent/ES2203793T3/es not_active Expired - Lifetime
- 1997-03-05 CN CN97193839A patent/CN1079796C/zh not_active Expired - Fee Related
- 1997-03-05 DK DK97914189T patent/DK0888353T3/da active
- 1997-03-05 BR BRPI9709443-9A patent/BR9709443B1/pt not_active IP Right Cessation
1998
- 1998-09-11 NO NO19984199A patent/NO313239B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
NO984199D0 (no)	1998-09-11
WO1997034895A1 (de)	1997-09-25
CN1079796C (zh)	2002-02-27
NO984199L (no)	1998-11-05
NO313239B1 (no)	2002-09-02
JP4326024B2 (ja)	2009-09-02
CN1216544A (zh)	1999-05-12
NZ331804A (en)	2000-04-28
US6051577A (en)	2000-04-18
EP0888353B1 (de)	2003-07-09
DK0888353T3 (da)	2003-10-27
AU716383B2 (en)	2000-02-24
ES2203793T3 (es)	2004-04-16
BR9709443A (pt)	1999-08-10
DE59710417D1 (de)	2003-08-14
KR20000064601A (ko)	2000-11-06
JP2000506537A (ja)	2000-05-30
PT888353E (pt)	2003-11-28
ATE244719T1 (de)	2003-07-15
AU2153497A (en)	1997-10-10
CA2249739A1 (en)	1997-09-25
EP0888353A1 (de)	1999-01-07

Publication	Publication Date	Title
BR9709443B1 (pt)	2009-05-05	n-7-heterociclil-pirrol[2,3-d]pirimidinas, bem como composições farmacêuticas compreendendo as mesmas.
BR9609617B1 (pt)	2010-07-27	derivados de 7h-pirrol[2,3-d]pirimidina, e composição farmacêutica.
BR9811956B1 (pt)	2010-06-01	naftiridinonas e composição farmacêutica compreendendo as mesmas.
AP2000001996A0 (en)	2000-12-31	Heterocyclic inhibitors of P38.
BG104813A (bg)	2001-08-31	Заместени индолинони с инхибиращ ефект върху кинази и комплекси циклин/cdk
AP9901435A0 (en)	1999-03-31	Bicycle heteroaromatic compounds as protein tyrosine kinase inhibitors.
DE59903921D1 (de)	2003-02-06	Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
EA200300248A1 (ru)	2003-08-28	Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции
BG103575A (en)	2000-06-30	SUBSTITUTED NITROGENCONTAINING HETEROCYCLES AS p38 PROTEINKINASE INHIBIRORS
DE60314603D1 (de)	2007-08-09	Zusammensetzungen brauchbar als protein-kinase- inhibitoren
BR0008365A (pt)	2001-11-13	2-amino-6-anilino-purinas e o seu uso comomedicamento
MY117696A (en)	2004-07-31	INHIBITORS OF p38
JO2534B1 (en)	2010-09-05	Pyrimidines carrying alternatives of sulfoximine as CDK and / or VEGF inhibitors and their production and use as pharmaceutical agents
DK1000035T3 (da)	2003-03-17	Substituerede 6-phenylphenanthridiner
MX9702307A (es)	1998-04-30	Pirrolo (2,3-d)pirimidinas y su uso.
ATE450530T1 (de)	2009-12-15	Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
BG104938A (bg)	2001-06-29	Заместени индолинони, тяхното получаване и тяхното приложение като лекарствени средства
MXPA03010269A (es)	2004-05-05	Derivados de 2,5-disubstituida piridina, pirimidina, piridazina y 1,2,4-triazina para usarse como inhibidores de p38.
IL118167A0 (en)	1996-09-12	Pyrazolo (1,5a) pyrimidines their preparation and use
BG105763A (en)	2002-03-29	Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

Legal Events

Date	Code	Title	Description
2005-10-18	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2007-09-04	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2008-12-09	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2009-06-02	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/06/2009, OBSERVADAS AS CONDICOES LEGAIS.
2013-10-08	B22O	Other matters related to patents and certificates of addition of invention: legal action concerning patent	Free format text: INPI-52400.062008/2013 ORIGEM: JUIZO DA 013A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0132270-62.2013.4.02.5101 ACAO DE NULIDADE DAS PATENTES SUBMETIDAS AO MAILBOX (ART. 229, PARAGRAFO UNICO DA LPI); ALTERNATIVAMENTE, A DECRETACAO DA NULIDADE PARCIAL PARA CORRECAO DO PRAZO DE VIGENCIA; SUBSIDIARIAMENTE, CASO SE ENTENDA NAO SER O CASO DE NULIDADE, A CORRECAO DO ATO ADMINISTRATIVO PARA ADEQUACAO DA VIGENCIA DAS PATENTES. AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU:NIPPON KAYAKU KABUSHIKI KAISHA, NOVARTIS AG, NOVARTIS SA, NOVARTISINS, NOVARTIS CONSUMER HEALTH S.A.
2013-12-10	B24H	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi)	Free format text: EXTINCAO DEFINITIVA - ART. 78 INCISO IV DA LPI
2014-04-08	B19A	Notification of judicial decision: notification of judicial decision	Free format text: INPI-52400.104054/14 SECAO JUDICIARIA DO RIO DE JANEIRO-13A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO0001852-02.2014.4.02.5101 AUTOR:INPI-INSTITUTO NACIONAL DE PROPRIEDADE INDUSTRIAL REU(S):NOVARTIS AG (NOVARTIS AS)(NOVARTIS INC.) E NOVARTIS CONSUMER HEALTH S.A DECISAO:HOMOLOGO O ACORDO FIRMADO,JULGAMENTO EXTINTO O PROCESSO COM RESOLUCAO DE MERITO, FORTE NO ART.269,III DO CODIGO DE PROCESSO CIVIL.
2020-11-24	B24F	Patent annual fee: publication cancelled	Free format text: ANULADA A PUBLICACAO CODIGO 24.8 NA RPI NO 2240 DE 10/12/2013 POR TER SIDO INDEVIDA.
2021-08-24	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 16A, 17A, 18A, 19A E 20A RETRIBUICAO ANUAL.